Fast Five Quiz: Interstitial Nonidiopathic Pulmonary Fibrosis Management

Setu K. Patolia, MD, MPH

Disclosures

February 12, 2021

Diffuse parenchymal lung diseases (DPLDs) comprise a heterogeneous group of disorders that may be idiopathic, the classic illustration being idiopathic pulmonary fibrosis (IPF). Other forms of DPLD may be related to occupational, environmental, drug, or radiation exposure, or systemic illness such as collagen-vascular disease. Non-idiopathic pulmonary fibrosis (non-IPF) is associated with inflammation and characterized by chronic dyspnea, cough, loss of lung function, and overall decline in quality of life.

Choosing an appropriate therapy can be difficult due to a lack of precision in classifying the various forms of ILD, and it is often necessary to obtain tissue specimens for a definitive diagnosis. Outside of IPF, there are no established treatment paradigms for other forms of progressive fibrosing interstitial lung disease (ILD). Therapy is currently based on corticosteroids and/or immunomodulating agents, but response to these therapies varies, especially in more fibrosing forms of disease.

How much do you know about managing DPLDs? Test your knowledge with this quick quiz.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....